You are hereBlogs / admin's blog / Preclinical evaluation of the antitumor activity of bortezomib in combination with vitamin C
Preclinical evaluation of the antitumor activity of bortezomib in combination with vitamin C
Bannerman B, Xu L, Jones M, Tsu C, Yu J, Hales P, Monbaliu J, Fleming P, Dick L, Manfredi M, Claiborne C, Bolen J, Kupperman E, Berger A. Preclinical evaluation of the antitumor activity of bortezomib in combination with vitamin C or with epigallocatechin gallate, a component of green tea. Cancer Chemother Pharmacol. 2011 Mar 13. [Epub ahead of print] PubMed PMID: 21400028
No antagonism of bortezomib is seen in preclinical in vivo experiments, where EGCG or ascorbic acid plasma concentrations are commensurate with dietary or supplemental intake. The data suggest that patients receiving bortezomib treatment do not need to avoid normal dietary consumption of green tea, vitamin C-containing foods, or EGCG or vitamin C dietary supplements.
Access to Parenteral Thiamine
Biological Therapies supplies a range of registered injections containing parenteral thiamine.
See the TGA website: http://www.tga.gov.au/safety/alerts-medicine-ivthiamine-100728.htm
See also the SHPA website: SHPA Manufacturers Alerts (Thiamine Injection)
